<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Angew Chem Int Ed Engl</journal-id><journal-id journal-id-type="iso-abbrev">Angew. Chem. Int. Ed. Engl</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1521-3773</journal-id><journal-id journal-id-type="publisher-id">ANIE</journal-id><journal-title-group><journal-title>Angewandte Chemie (International Ed. in English)</journal-title></journal-title-group><issn pub-type="ppub">1433-7851</issn><issn pub-type="epub">1521-3773</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5488172</article-id><article-id pub-id-type="doi">10.1002/anie.201702403</article-id><article-id pub-id-type="publisher-id">ANIE201702403</article-id><article-categories><subj-group subj-group-type="overline"><subject>Communication</subject></subj-group><subj-group subj-group-type="heading"><subject>Communications</subject><subj-group subj-group-type="heading"><subject>Ratiometric Sensors</subject></subj-group></subj-group></article-categories><title-group><article-title>Bioluminescent Antibodies for Point&#x02010;of&#x02010;Care Diagnostics</article-title></title-group><contrib-group><contrib id="anie201702403-cr-0001" contrib-type="author"><name><surname>Xue</surname><given-names>Lin</given-names><prefix>Dr.</prefix></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4540-3386</contrib-id><xref ref-type="aff" rid="anie201702403-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="anie201702403-cr-0002" contrib-type="author"><name><surname>Yu</surname><given-names>Qiuliyang</given-names></name><xref ref-type="aff" rid="anie201702403-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="anie201702403-cr-0003" contrib-type="author"><name><surname>Griss</surname><given-names>Rudolf</given-names><prefix>Dr.</prefix></name><xref ref-type="aff" rid="anie201702403-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="anie201702403-cr-0004" contrib-type="author"><name><surname>Schena</surname><given-names>Alberto</given-names><prefix>Dr.</prefix></name><xref ref-type="aff" rid="anie201702403-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="anie201702403-cr-0005" contrib-type="author" corresp="yes"><name><surname>Johnsson</surname><given-names>Kai</given-names><prefix>Prof.</prefix></name><address><email>kai.johnsson@mpimf-heidelberg.mpg.de</email></address><xref ref-type="aff" rid="anie201702403-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="anie201702403-aff-0003">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="anie201702403-aff-0001">
<label><sup>1</sup></label>
<institution>Ecole Polytechnique F&#x000e9;d&#x000e9;rale de Lausanne (EPFL)</institution>
<named-content content-type="organisation-division">Institute of Chemical Sciences and Engineering (ISIC)</named-content>
<named-content content-type="organisation-division">NCCR in Chemical Biology</named-content>
<named-content content-type="post-code">1015</named-content>
<named-content content-type="city">Lausanne</named-content>
<country country="CH">Switzerland</country>
</aff><aff id="anie201702403-aff-0002">
<label><sup>2</sup></label>
<institution>Lucentix SA</institution>
<named-content content-type="organisation-division">EPFL Innovation Park</named-content>
<named-content content-type="organisation-division">B&#x000e2;timent C</named-content>
<named-content content-type="post-code">1015</named-content>
<named-content content-type="city">Lausanne</named-content>
<country country="CH">Switzerland</country>
</aff><aff id="anie201702403-aff-0003">
<label><sup>3</sup></label>
<institution>Max-Planck-Institute for Medical Research</institution>
<named-content content-type="organisation-division">Department of Chemical Biology</named-content>
<named-content content-type="post-code">69120</named-content>
<named-content content-type="city">Heidelberg</named-content>
<country country="DE">Germany</country>
</aff><pub-date pub-type="epub"><day>16</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="ppub"><day>12</day><month>6</month><year>2017</year></pub-date><volume>56</volume><issue>25</issue><issue-id pub-id-type="doi">10.1002/anie.v56.25</issue-id><fpage>7112</fpage><lpage>7116</lpage><history><date date-type="received"><day>06</day><month>3</month><year>2017</year></date><date date-type="rev-recd"><day>11</day><month>4</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 Wiley&#x02010;VCH Verlag GmbH & Co. KGaA, Weinheim <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. Published by Wiley-VCH Verlag GmbH &#x00026; Co. KGaA.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:ANIE-56-7112.pdf"/><abstract><title>Abstract</title><p>We introduce a general method to transform antibodies into ratiometric, bioluminescent sensor proteins for the no&#x02010;wash quantification of analytes. Our approach is based on the genetic fusion of antibody fragments to NanoLuc luciferase and SNAP&#x02010;tag, the latter being labeled with a synthetic fluorescent competitor of the antigen. Binding of the antigen, here synthetic drugs, by the sensor displaces the tethered fluorescent competitor from the antibody and disrupts bioluminescent resonance energy transfer (BRET) between the luciferase and fluorophore. The semisynthetic sensors display a tunable response range (submicromolar to submillimolar) and large dynamic range (&#x00394;<italic>R</italic>
<sub>max</sub>&#x0003e;500&#x02009;%), and they permit the quantification of analytes through spotting of the samples onto paper followed by analysis with a digital camera.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="anie201702403-kwd-0001">antibodies</kwd><kwd id="anie201702403-kwd-0002">bioluminescence</kwd><kwd id="anie201702403-kwd-0003">point-of-care monitoring</kwd><kwd id="anie201702403-kwd-0004">sensors</kwd><kwd id="anie201702403-kwd-0005">therapeutic drug monitoring</kwd></kwd-group><funding-group><award-group><funding-source>NCCR Chemical Biology</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Swiss National Science Foundation</funding-source></award-group></funding-group><funding-group><award-group><funding-source>&#x000c9;cole Polytechnique F&#x000e9;d&#x000e9;rale de Lausanne</funding-source></award-group></funding-group><counts><fig-count count="6"/><table-count count="1"/><ref-count count="26"/><page-count count="5"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>anie201702403</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 12, 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.2 mode:remove_FC converted:06.07.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="anie201702403-self">L. Xue, Q. Yu, R. Griss, A. Schena, K. Johnsson, <italic>Angew. Chem. Int. Ed.</italic>
<bold>2017</bold>, <italic>56</italic>, 7112.</mixed-citation>
</p></notes></front><body><p>The precise and reliable quantification of analytes in point&#x02010;of&#x02010;care (PoC) settings without the need for specialized instrumentation benefits public health in developed as well as developing countries. One of the challenges in the field is the development of generally applicable approaches to quantify drugs for PoC therapeutic drug monitoring (TDM).<xref rid="anie201702403-bib-0001" ref-type="ref">1</xref> TDM is mostly based on mass&#x02010;spectrometry or antibody&#x02010;based immunoassays, both of which require specialized instrumentation or multiple assay steps, thus making their use for PoC applications by non&#x02010;expert users problematic.<xref rid="anie201702403-bib-0002" ref-type="ref">2</xref>, <xref rid="anie201702403-bib-0003" ref-type="ref">3</xref> Even though the generation of specific antibodies against various analytes is a routine procedure, approaches to transfer the specific binding of antibodies into a signal readout compatible with cheap and portable devices are needed.</p><p>We recently introduced a new class of ratiometric and bioluminescent biosensors for PoC TDM.<xref rid="anie201702403-bib-0004" ref-type="ref">4</xref> These luciferase&#x02010;based indicators of drugs (LUCIDs) are comprised of a SNAP&#x02010;tag, a blue&#x02010;emitting NanoLuc luciferase, and a binding protein for the drug of interest. SNAP&#x02010;tag is labeled with a molecule composed of a ligand for the binding protein and a red&#x02010;emitting fluorophore suitable for BRET.<xref rid="anie201702403-bib-0005" ref-type="ref">5</xref>, <xref rid="anie201702403-bib-0006" ref-type="ref">6</xref>, <xref rid="anie201702403-bib-0007" ref-type="ref">7</xref> Binding of the drug by the sensor displaces the tethered fluorescent competitor from the binding protein, which disrupts bioluminescent resonance energy transfer (BRET) between the luciferase and the fluorophore and thus shifts the color from red to blue in a drug&#x02010;concentration&#x02010;dependent manner, thereby permitting the quantification of drugs by spotting samples onto paper, followed by analysis with a digital camera (Figure&#x02005;<xref rid="anie201702403-fig-0001" ref-type="fig">1</xref>&#x02009;a). However, up to now, no general strategy exists to identify suitable binding proteins. Here, we demonstrate how antibodies can be used as the binding proteins in LUCIDs, thereby establishing a general design principle for PoC&#x02010;compatible biosensors towards a basically unlimited number of analytes. Antibodies have three features that make them ideal binding proteins for LUCIDs: 1)&#x02005;all antibodies share a common three&#x02010;dimensional structure, which removes the need to optimize the sensor geometry for each individual senor; 2)&#x02005;the generation of antibodies against antigens of interest, including small molecules, is a routine procedure; 3)&#x02005;small&#x02010;molecule antigens need to be tethered to a carrier via a linker for antibody generation, thereby automatically providing a tethered ligand for sensor generation.
</p><fig fig-type="Figure" xml:lang="en" id="anie201702403-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The design of LUCIDs for PoC diagnostics. a)&#x02005;Schematic representation of the paper&#x02010;based device. The LUCID is a fusion protein of SNAP&#x02010;tag, NanoLuc luciferase (NLuc), and a binding protein (BP). SNAP&#x02010;tag is labeled with a molecule containing a fluorophore (red star) and a ligand (green ball) that binds to BP. The filter paper was printed with wax circles and the signal was collected by a digital camera. b)&#x02005;The variable fragment of the methotrexate antibody (PDB&#x02005;ID: 4OCX) bound to methotrexate (yellow). The N&#x02010;termini of both chains are indicated in green. The three CDRs (H1&#x02010;3, blue) on the heavy chain (light blue) and three CDRs (L1&#x02010;3, red) on the light chain (pink) are involved in antigen binding. c)&#x02005;In Fab&#x02010;based LUCIDs, the binding protein is an antibody Fab fragment. SNAP&#x02010;tag and NanoLuc are attached to the light chain.</p></caption><graphic id="nlm-graphic-3" xlink:href="ANIE-56-7112-g001"/></fig><p>To generate antibody&#x02010;based LUCIDs, we focused on the antigen&#x02010;binding (Fab) fragment of antibodies. Fabs, which contain the complementary&#x02010;determining regions (CDRs) of antibodies, can be expressed as fusion proteins and are monovalent.<xref rid="anie201702403-bib-0008" ref-type="ref">8</xref>, <xref rid="anie201702403-bib-0009" ref-type="ref">9</xref>, <xref rid="anie201702403-bib-0010" ref-type="ref">10</xref> The latter fact facilitates their use as LUCIDs. The N&#x02005;termini of both the heavy and light chains are in close proximity to the binding site, which should result in high BRET in the closed state of the biosensor (Figure&#x02005;<xref rid="anie201702403-fig-0001" ref-type="fig">1</xref>&#x02009;b). The CDR loop 3 of both chains are close to the respective N&#x02005;termini of each chain, but CDR H3s generally show much more variation in both length and space.<xref rid="anie201702403-bib-0011" ref-type="ref">11</xref>, <xref rid="anie201702403-bib-0012" ref-type="ref">12</xref>, <xref rid="anie201702403-bib-0013" ref-type="ref">13</xref> In order to make the approach as general as possible, we therefore decided to attach SNAP&#x02010;tag and NanoLuc luciferase to the light chain of the Fab fragment (Figure&#x02005;<xref rid="anie201702403-fig-0001" ref-type="fig">1</xref>&#x02009;c). A rigid proline linker (Pro30) was introduced between SNAP&#x02010;tag and NanoLuc to lower the BRET efficiency in the open state of the sensor by increasing the distance between NanoLuc and the tethered fluorophore.<xref rid="anie201702403-bib-0014" ref-type="ref">14</xref> We validated our design principle by generating Fab&#x02010;based sensor proteins for three distinct drugs, methotrexate, theophylline and quinine (Figure&#x02005;<xref rid="anie201702403-fig-0002" ref-type="fig">2</xref>),<xref rid="anie201702403-bib-0015" ref-type="ref">15</xref> and used the sensors for paper&#x02010;based PoC quantification of drug levels in human serum and blood samples.
</p><fig fig-type="Figure" xml:lang="en" id="anie201702403-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Antibody&#x02010;binding of methotrexate&#x02005;(a), theophylline&#x02005;(b), and quinine&#x02005;(c). The chemical structures of the three drugs are shown on the left. The crystal structures of antibodies with the methotrexate (PDB&#x02005;ID: 4OCX), theophylline derivative (PDB&#x02005;ID: 5BMF), and quinine (PDB&#x02005;ID: 4UIN) were superimposed, showing the interactions of the residues with the ligands (carbon atoms in green). Extensive hydrogen bonding (dotted orange lines) links the three antigens to the antibodies, either directly or via water molecules (red balls).</p></caption><graphic id="nlm-graphic-5" xlink:href="ANIE-56-7112-g002"/></fig><p>The response range of LUCIDs can be tuned by modifying the tethered ligand. When raising antibodies against small molecules, the affinity for the tethered molecule is usually higher than that for the free small molecule. The effective molarity of tethered ligands in our sensors can be estimated to be around 100&#x02005;&#x003bc;<sc>m</sc>. Assuming that the same tethered molecule would be used for antibody and LUCID generation, the response range for antibody&#x02010;based LUCIDs would be more than 100&#x02005;&#x003bc;<sc>m</sc> and therefore above the therapeutic concentration of most drugs. We show here how modification of the structure of the tethered ligand or mutagenesis of the antibody binding site permits lowering of the response range of LUCIDs to the nanomolar range. Taking advantage of structural information on the antibody&#x02013;drug interactions (Figure&#x02005;<xref rid="anie201702403-fig-0002" ref-type="fig">2</xref>),<xref rid="anie201702403-bib-0016" ref-type="ref">16</xref>, <xref rid="anie201702403-bib-0017" ref-type="ref">17</xref>, <xref rid="anie201702403-bib-0018" ref-type="ref">18</xref> we prepared two tethered ligands for each sensor protein (Figure&#x02005;<xref rid="anie201702403-fig-0003" ref-type="fig">3</xref>). For the methotrexate LUCID, we first decreased the picomolar binding affinity of the antibody towards methotrexate by introducing the mutation N36S on the heavy chain of the anti&#x02010;methotrexate Fab. The first tethered ligand (MTX<sub>1</sub>, Figure&#x02005;<xref rid="anie201702403-fig-0003" ref-type="fig">3</xref>) for the methotrexate LUCID was then generated by attaching an ethylene glycol linker directly to 4&#x02010;amino&#x02010;4&#x02010;deoxy&#x02010;<italic>N</italic>&#x02010;methylpteroic acid (DAMPA), thereby removing hydrogen bonding between the glutamic acid of methotrexate and two asparagine residues of the antibody. For the second tethered ligand (MTX<sub>2</sub>), we also removed the methyl group to further decrease the binding affinity of the ligand. The anti&#x02010;theophylline Fab fragment binds to its antigen through several hydrogen bonds, including those between the amide bond on the linker and Tyr37 on the light chain and Arg53 on the heavy chain (Figure&#x02005;<xref rid="anie201702403-fig-0002" ref-type="fig">2</xref>&#x02009;b). Attaching a linker to N7 of theophylline (Theo<sub>1</sub>) or shifting the position of the amide bond (Theo<sub>2</sub>) should thus decrease the binding affinity of the tethered ligands (Figure&#x02005;<xref rid="anie201702403-fig-0003" ref-type="fig">3</xref>). In the structure of anti&#x02010;quinine Fab fragment (Figure&#x02005;<xref rid="anie201702403-fig-0002" ref-type="fig">2</xref>&#x02009;c), the quinine interacts directly with Glu99 on the heavy chain and indirectly with Asn92 on the light chain of the Fab. Alkylation of the quinolinic or quinuclidinic nitrogen was thereby performed to yield the ligands Quin<sub>1</sub> and Quin<sub>2</sub> (Figure&#x02005;<xref rid="anie201702403-fig-0003" ref-type="fig">3</xref>).
</p><fig fig-type="Figure" xml:lang="en" id="anie201702403-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Molecules used for semisynthesis of the sensor proteins. The benzylguanine group serves as the reactive moiety for SNAP&#x02010;tag labeling (blue). The fluorophore Cy3 is colored in red. The ligands for different analytes are shown as R groups, which conjugate to the polyethylene glycol linker through amide bonds (green).</p></caption><graphic id="nlm-graphic-7" xlink:href="ANIE-56-7112-g003"/></fig><p>All of the sensor proteins were obtained through co&#x02010;expression of heavy and light chains from mammalian cells (Table&#x02005;S1 and Figure&#x02005;S1 in the Supporting Information). After labeling SNAP&#x02010;tag with the benzylguanine derivatives, the bioluminescence response of the resulting six LUCIDs in human serum was measured as a function of the corresponding analyte concentrations (Table&#x02005;<xref rid="anie201702403-tbl-0001" ref-type="table-wrap">1</xref>). For all LUCIDs, titration with increasing concentrations of analyte led to a decrease in the emission of Cy3 and an increase in NanoLuc emission, which is in line with the free analyte displacing the tethered ligands (Figure&#x02005;<xref rid="anie201702403-fig-0004" ref-type="fig">4</xref>&#x02009;a&#x02013;c and Figures&#x02005;S2&#x02013;4). The maximal emission ratio changes (&#x00394;<italic>R</italic>
<sub>max</sub>) were all larger than 500&#x02009;%, and up to 2155&#x02009;% for the theophylline sensor Theo<sub>1</sub>&#x02010;Lucid (Table&#x02005;<xref rid="anie201702403-tbl-0001" ref-type="table-wrap">1</xref>). To the best of our knowledge, this is the highest dynamic range for any BRET&#x02010;based ratiometric biosensor reported so far. For each sensor protein, tuning the binding affinities of the tethered ligands shifted the c<sub>50</sub> values, defined as the analyte concentration that resulted in 50&#x02009;% of the maximum ratio change, and permitted the detection of analyte levels from submicromolar to submillimolar concentrations (Table&#x02005;<xref rid="anie201702403-tbl-0001" ref-type="table-wrap">1</xref>).
</p><fig fig-type="Figure" xml:lang="en" id="anie201702403-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>LUCIDs for methotrexate, theophylline, and quinine. Emission spectra of 5&#x02005;n<sc>m</sc> MTX<sub>1</sub>&#x02010;Lucid&#x02005;(a), Theo<sub>1</sub>&#x02010;Lucid&#x02005;(b), and Quin<sub>2</sub>&#x02010;Lucid&#x02005;(c) in human serum spiked with known concentrations of the corresponding analyte. Emission ratios of methotrexate LUCIDs&#x02005;(d), theophylline LUCIDs&#x02005;(e), and quinine LUCIDs&#x02005;(f) as a function of analyte concentration. The measurements were performed on paper spotted with 5&#x02005;&#x003bc;L sample (50&#x02005;m<sc>m</sc> HEPES, 50&#x02005;m<sc>m</sc> NaCl, pH&#x02005;7.45, 50&#x02009;% (v/v) serum, 1/100 furimazine). The data (mean&#x000b1;SD) are fitted to a single&#x02010;site binding isotherm (dashed line). Insets: pictures of the paper&#x02010;based devices in the detection of serum samples with the corresponding analytes (Top: LUCIDs with low c<sub>50</sub> values; Bottom: LUCIDs with high c<sub>50</sub> values).</p></caption><graphic id="nlm-graphic-9" xlink:href="ANIE-56-7112-g004"/></fig><table-wrap id="anie201702403-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>The &#x00394;<italic>R</italic>
<sub>max</sub>, <italic>c</italic>
<sub>50</sub>, and response range of the LUCIDs for the three drugs.<sup>[a]</sup>
</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" span="1"/><col align="left" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Sensor</th><th align="left" valign="top" rowspan="1" colspan="1">&#x00394;<italic>R</italic>
<sub>max</sub>&#x02005;[%]</th><th align="char" valign="top" rowspan="1" colspan="1">
<italic>c</italic>
<sub>50</sub>&#x02005;[&#x003bc;<sc>m</sc>]</th><th align="left" valign="top" rowspan="1" colspan="1">Response Range<sup>[b]</sup>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">MTX<sub>1</sub>&#x02010;Lucid</td><td align="left" valign="top" rowspan="1" colspan="1">1064</td><td align="char" valign="top" rowspan="1" colspan="1">12.74&#x000b1;1.55</td><td rowspan="2" align="left" valign="top" colspan="1">53&#x02005;n<sc>m</sc> &#x02212;0.13&#x02005;m<sc>m</sc>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MTX<sub>2</sub>&#x02010;Lucid</td><td align="left" valign="top" rowspan="1" colspan="1">863</td><td align="char" valign="top" rowspan="1" colspan="1">0.53&#x000b1;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Theo<sub>1</sub>&#x02010;Lucid</td><td align="left" valign="top" rowspan="1" colspan="1">2155</td><td align="char" valign="top" rowspan="1" colspan="1">92.96&#x000b1;5.02</td><td rowspan="2" align="left" valign="top" colspan="1">0.84&#x02005;&#x003bc;<sc>m</sc> &#x02212;0.93&#x02005;m<sc>m</sc>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Theo<sub>2</sub>&#x02010;Lucid</td><td align="left" valign="top" rowspan="1" colspan="1">933</td><td align="char" valign="top" rowspan="1" colspan="1">8.44&#x000b1;0.17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quin<sub>1</sub>&#x02010;Lucid</td><td align="left" valign="top" rowspan="1" colspan="1">562</td><td align="char" valign="top" rowspan="1" colspan="1">4.87&#x000b1;0.90</td><td rowspan="2" align="left" valign="top" colspan="1">0.49&#x02005;&#x003bc;<sc>m</sc> &#x02212;0.59&#x02005;m<sc>m</sc>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quin<sub>2</sub>&#x02010;Lucid</td><td align="left" valign="top" rowspan="1" colspan="1">1036</td><td align="char" valign="top" rowspan="1" colspan="1">59.12&#x000b1;8.51</td></tr></tbody></table><table-wrap-foot><fn id="anie201702403-tnote-0001"><p>[a]&#x02005;The measurements were performed in human serum (50&#x02005;m<sc>m</sc> HEPES, 50&#x02005;m<sc>m</sc> NaCl, pH&#x02005;7.45, 50&#x02009;% (v/v) serum) and the sensor concentration is 5&#x02005;n<sc>m</sc>. [b]&#x02009;The response range represents the combined response ranges of two LUCIDs for each analyte.</p></fn></table-wrap-foot><permissions><copyright-holder>Wiley&#x02010;VCH Verlag GmbH &#x00026; Co. KGaA</copyright-holder></permissions></table-wrap><p>It is noteworthy that the high performance of the Fab&#x02010;based LUCIDs was achieved without any complex geometry optimization, such as circular permutation of the binding proteins, thus underlining the generality of the approach to transform the antibodies into bioluminescent sensors.</p><p>Kinetic experiments showed that for all these sensors, the signal reached equilibrium within 15&#x02005;min (Figure&#x02005;S5), thus making them suitable for rapid PoC testing. To evaluate the sensors for possible cross&#x02010;reactivity, we next titrated them with different potential drug metabolites or known interference compounds. 7&#x02010;hydroxy methotrexate, which is the major metabolite of methotrexate,<xref rid="anie201702403-bib-0019" ref-type="ref">19</xref> did not induce an obvious ratio response in either methotrexate sensor, while the minor metabolite 4&#x02010;amino&#x02010;4&#x02010;deoxy&#x02010;<italic>N</italic>&#x02010; methylpteroic acid (DAMPA) showed a five&#x02010;fold larger c<sub>50</sub> and should not interference with the detection of methotrexate (Figure&#x02005;S6).<xref rid="anie201702403-bib-0020" ref-type="ref">20</xref> Key metabolites of theophylline and compounds structurally similar to theophylline, including 1,3&#x02010;dimethyluric acid, 1&#x02010;methylxanthine, and 3&#x02010;methylxanthine,<xref rid="anie201702403-bib-0021" ref-type="ref">21</xref> did not interfere with the measurements of theophylline (using Theo<sub>1</sub> as tethered ligand) in the therapeutic relevant concentration range of the drug (Figure&#x02005;S7). The key metabolite of quinine, 3&#x02010;hydroxyquinine,<xref rid="anie201702403-bib-0022" ref-type="ref">22</xref> and other quinoline&#x02010;based antimalaria drugs commonly used in a combination with quinine for medical treatments, also showed negligible signal response, thus indicating that the quinine LUCIDs show excellent specificity (Figure&#x02005;S8). These data showed that the antibodies preserved their high specificity during the transformation into bioluminescent sensors.</p><p>In order to transfer these antibody&#x02010;based biosensors into PoC devices suitable for easy, portable, and inexpensive diagnostics, we constructed paper&#x02010;based devices that allowed simple quantification with a digital camera.<xref rid="anie201702403-bib-0004" ref-type="ref">4</xref> We therefore investigated whether the Fab&#x02010;based sensors would be compatible with measurements on paper. For this, we pretreated paper with bovine serum albumin and the non&#x02010;ionic detergent TWEEN&#x02005;20 to reduce adsorption of the sensor and analytes, as well as to improve diffusion of the spotted liquid.<xref rid="anie201702403-bib-0023" ref-type="ref">23</xref> The LUCIDs were then lyophilized on the pre&#x02010;treated paper for later use. Titrations with samples (5&#x02005;&#x003bc;L each) on paper exhibited similar results to those observed in serum buffer (Table&#x02005;S2). Using a digital camera, the analyte&#x02010;dependent color transition from red to blue was also recorded (Figure&#x02005;<xref rid="anie201702403-fig-0004" ref-type="fig">4</xref>&#x02009;d&#x02013;f, inset). When transferring the RGB pixel data of the pictures into the CIE1931 xy chromaticity diagram, which is an objective specification of the quality of a color regardless of its luminance, the analyte&#x02010;dependent color transitions displayed good linearity, confirming the color mixing of red and blue with different ratios (Figure&#x02005;S9).<xref rid="anie201702403-bib-0024" ref-type="ref">24</xref>, <xref rid="anie201702403-bib-0025" ref-type="ref">25</xref> The ratio values between the average intensity per pixel in the blue and red color channel were calculated according to the known method (Figure&#x02005;<xref rid="anie201702403-fig-0004" ref-type="fig">4</xref>&#x02009;d&#x02013;f).<xref rid="anie201702403-bib-0004" ref-type="ref">4</xref> The c<sub>50</sub> values obtained by the camera&#x02010;based measurements agreed well with those measured by the microplate reader (Table&#x02005;S2), thus suggesting that the digital&#x02010;camera&#x02010;based testing was a reliable method to provide laboratory&#x02010;quality results for the quantification of drugs on paper with a minimal sample volume.</p><p>We next spiked the three drugs in HEPES buffer and measured the concentrations using the paper&#x02010;based devices. By comparing the results to those obtained with a UV/Vis spectrophotometric method, we observed a very good correlation (<italic>R=</italic>0.994) between the results measured by the two methods (Figure&#x02005;<xref rid="anie201702403-fig-0005" ref-type="fig">5</xref>). Furthermore, the LUCIDs also exhibited a very good average inter&#x02010;assay coefficient of variation of 14.8&#x02009;%. The paper strips with the dried LUCIDs did not show a significant decrease in performance after 35&#x02005;days of storage at room temperature (Table&#x02005;S2). These results clearly demonstrated the suitability of the paper&#x02010;based devices for PoC TDM.
</p><fig fig-type="Figure" xml:lang="en" id="anie201702403-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Correlation of the results obtained for the spiked samples (black: theophylline, red: methotrexate, and blue: quinine) using a traditional UV/Vis spectrophotometric method and LUCID. The LUCID measurements were performed on paper by spotting 5&#x02005;&#x003bc;L sample/serum mixture (50&#x02005;m<sc>m</sc> HEPES, 50&#x02005;m<sc>m</sc> NaCl, pH&#x02005;7.45, 50&#x02009;% (v/v) serum, 1/100 furimazine), and the UV/Vis measurements in HEPES buffer (50&#x02005;m<sc>m</sc> HEPES, 50&#x02005;m<sc>m</sc> NaCl, pH&#x02005;7.45). Each LUCID measurement is given as the mean&#x000b1;SD of three independent measurements. Regression analysis yielded a Pearson correlation coefficient <italic>R</italic>=0.994.</p></caption><graphic id="nlm-graphic-11" xlink:href="ANIE-56-7112-g005"/></fig><p>We further used our paper&#x02010;based devices for the analysis of whole&#x02010;blood samples. Blood components such as hemoglobin are known to interfere with luciferase&#x02010;based measurements.<xref rid="anie201702403-bib-0026" ref-type="ref">26</xref> However, we found that a simple dilution of the blood into HEPES buffer (1/10) sufficiently removed this effect in our diagnostic scheme. We successfully set up calibration curves from the diluted blood samples (Figure&#x02005;S10) for all three drugs. For these experiments, we used the LUCIDs with smaller c<sub>50</sub> values, since they are more suitable for the analysis of ten&#x02010;fold diluted samples. The good match of the c<sub>50</sub> values with those observed from serum samples and high maximal ratio changes demonstrate that the paper&#x02010;based devices permit the direct PoC quantification of drugs in diluted blood samples.</p><p>In summary, we devised a general approach to transform antibodies into bioluminescent sensor proteins for therapeutic drugs. The sensors show high specificity, a tunable response range, and a large dynamic range. On paper&#x02010;based devices, they permit the PoC quantification of drug levels in serum/blood by using a low&#x02010;cost digital camera. The generation of specific antibodies towards almost any molecule is a well&#x02010;established technique, and our work therefore establishes a general design principle for PoC therapeutic drug monitoring that should ultimately improve patient care and bring benefits to low&#x02010;resource locations.</p><sec disp-level="2" id="anie201702403-sec-0003" sec-type="conflict-of-interest"><title>Conflict of interest</title><p>The authors declare no conflict of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><p>As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re&#x02010;organized for online delivery, but are not copy&#x02010;edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.</p></supplementary-material><supplementary-material content-type="local-data"><caption><p>Supplementary</p></caption><media xlink:href="ANIE-56-7112-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="anie201702403-sec-0002"><title>Acknowledgements</title><p>This work was supported by funding from the Swiss National Science Foundation, the NCCR Chemical Biology, and EPFL. We thank Dr. David Hacker, Laurence Durrer, and Soraya Quinche for the help of protein expression.</p></ack><ref-list><ref id="anie201702403-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="anie201702403-cit-0001">
<string-name>
<given-names>B.</given-names>
<surname>Sanavio</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Krol</surname>
</string-name>, <source>Front. Bioeng. Biotechnol.</source>
<year>2015</year>, <volume>3</volume>, <fpage>20</fpage>.<pub-id pub-id-type="pmid">25767794</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="anie201702403-cit-0002">
<string-name>
<given-names>F.</given-names>
<surname>Saint-Marcoux</surname>
</string-name>, <string-name>
<given-names>F.-L.</given-names>
<surname>Sauvage</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Marquet</surname>
</string-name>, <source>Anal. Bioanal. Chem.</source>
<year>2007</year>, <volume>388</volume>, <fpage>1327</fpage>&#x02013;<lpage>1349</lpage>.<pub-id pub-id-type="pmid">17520242</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0003"><label>3</label><mixed-citation publication-type="book" id="anie201702403-cit-0003">
<string-name>
<given-names>A.</given-names>
<surname>Dasgupta</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Datta</surname>
</string-name>, <source>Handbook of Drug Monitoring Methods</source>, <publisher-name>Humana</publisher-name>, <publisher-loc>Totowa, NJ</publisher-loc>, <year>2008</year>, pp.&#x02005;<fpage>67</fpage>&#x02013;<lpage>86</lpage>.</mixed-citation></ref><ref id="anie201702403-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="anie201702403-cit-0004">
<string-name>
<given-names>R.</given-names>
<surname>Griss</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Schena</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Reymond</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Patiny</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Werner</surname>
</string-name>, <string-name>
<given-names>C. E.</given-names>
<surname>Tinberg</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Baker</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Johnsson</surname>
</string-name>, <source>Nat. Chem. Biol.</source>
<year>2014</year>, <volume>10</volume>, <fpage>598</fpage>&#x02013;<lpage>603</lpage>.<pub-id pub-id-type="pmid">24907901</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="anie201702403-cit-0005">
<string-name>
<given-names>R.</given-names>
<surname>Arts</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>den&#x02005;Hartog</surname>
</string-name>, <string-name>
<given-names>S. E.</given-names>
<surname>Zijlema</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Thijssen</surname>
</string-name>, <string-name>
<given-names>S. H. E.</given-names>
<surname>van&#x02005;der&#x02005;Beelen</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Merkx</surname>
</string-name>, <source>Anal. Chem.</source>
<year>2016</year>, <volume>88</volume>, <fpage>4525</fpage>&#x02013;<lpage>4532</lpage>.<pub-id pub-id-type="pmid">27018236</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="anie201702403-cit-0006">
<string-name>
<given-names>R.</given-names>
<surname>Arts</surname>
</string-name>, <string-name>
<given-names>S. J. A.</given-names>
<surname>Aper</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Merkx</surname>
</string-name>, <source>Methods Enzymol.</source>
<year>2017</year>, <volume>589</volume>, <fpage>87</fpage>&#x02013;<lpage>114</lpage>.<pub-id pub-id-type="pmid">28336075</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="anie201702403-cit-0007">
<string-name>
<given-names>J.</given-names>
<surname>Bacart</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Corbel</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Jockers</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Bach</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Couturier</surname>
</string-name>, <source>Biotechnol. J.</source>
<year>2008</year>, <volume>3</volume>, <fpage>311</fpage>&#x02013;<lpage>324</lpage>.<pub-id pub-id-type="pmid">18228541</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="anie201702403-cit-0008">
<string-name>
<given-names>Y.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Gutshall</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Jiang</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Baker</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Beil</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Obmolova</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Carton</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Taudte</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Amegadzie</surname>
</string-name>, <source>Protein Expression Purif.</source>
<year>2009</year>, <volume>67</volume>, <fpage>182</fpage>&#x02013;<lpage>189</lpage>.</mixed-citation></ref><ref id="anie201702403-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="anie201702403-cit-0009">
<string-name>
<given-names>B. H.</given-names>
<surname>Biela</surname>
</string-name>, <string-name>
<given-names>L. A.</given-names>
<surname>Khawli</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Hu</surname>
</string-name>, <string-name>
<given-names>A. L.</given-names>
<surname>Epstein</surname>
</string-name>, <source>Cancer Biother. Radiopharm.</source>
<year>2003</year>, <volume>18</volume>, <fpage>339</fpage>&#x02013;<lpage>353</lpage>.<pub-id pub-id-type="pmid">12954121</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="anie201702403-cit-0010">
<string-name>
<given-names>P.</given-names>
<surname>Holliger</surname>
</string-name>, <string-name>
<given-names>P. J.</given-names>
<surname>Hudson</surname>
</string-name>, <source>Nat. Biotechnol.</source>
<year>2005</year>, <volume>23</volume>, <fpage>1126</fpage>&#x02013;<lpage>1136</lpage>.<pub-id pub-id-type="pmid">16151406</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="anie201702403-cit-0011">
<string-name>
<given-names>H.</given-names>
<surname>Shirai</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Kidera</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Nakamura</surname>
</string-name>, <source>FEBS Lett.</source>
<year>1999</year>, <volume>455</volume>, <fpage>188</fpage>&#x02013;<lpage>197</lpage>.<pub-id pub-id-type="pmid">10428499</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="anie201702403-cit-0012">
<string-name>
<given-names>C.</given-names>
<surname>Chothia</surname>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>Lesk</surname>
</string-name>, <source>J. Mol. Biol.</source>
<year>1987</year>, <volume>196</volume>, <fpage>901</fpage>&#x02013;<lpage>917</lpage>.<pub-id pub-id-type="pmid">3681981</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="anie201702403-cit-0013">
<string-name>
<given-names>J. L.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Davis</surname>
</string-name>, <source>Immunity</source>
<year>2000</year>, <volume>13</volume>, <fpage>37</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">10933393</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="anie201702403-cit-0014">
<string-name>
<given-names>M. A.</given-names>
<surname>Brun</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Griss</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Reymond</surname>
</string-name>, <string-name>
<given-names>K.-T.</given-names>
<surname>Tan</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Piguet</surname>
</string-name>, <string-name>
<given-names>R. J. R. W.</given-names>
<surname>Peters</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Vogel</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Johnsson</surname>
</string-name>, <source>J. Am. Chem. Soc.</source>
<year>2011</year>, <volume>133</volume>, <fpage>16235</fpage>&#x02013;<lpage>16242</lpage>.<pub-id pub-id-type="pmid">21879732</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="anie201702403-cit-0015">
<string-name>
<given-names>M.</given-names>
<surname>Schulz</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Iwersen-Bergmann</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Andresen</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Schmoldt</surname>
</string-name>, <source>Crit. Care</source>
<year>2012</year>, <volume>16</volume>, R<fpage>136</fpage>.<pub-id pub-id-type="pmid">22770392</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="anie201702403-cit-0016">
<string-name>
<given-names>S.</given-names>
<surname>Gayda</surname>
</string-name>, <string-name>
<given-names>K. L.</given-names>
<surname>Longenecker</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Manoj</surname>
</string-name>, <string-name>
<given-names>R. A.</given-names>
<surname>Judge</surname>
</string-name>, <string-name>
<given-names>S. C.</given-names>
<surname>Saldana</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Ruan</surname>
</string-name>, <string-name>
<given-names>K. M.</given-names>
<surname>Swift</surname>
</string-name>, <string-name>
<given-names>S. Y.</given-names>
<surname>Tetin</surname>
</string-name>, <source>Biochemistry</source>
<year>2014</year>, <volume>53</volume>, <fpage>3719</fpage>&#x02013;<lpage>3726</lpage>.<pub-id pub-id-type="pmid">24832237</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="anie201702403-cit-0017">
<string-name>
<given-names>A.</given-names>
<surname>Bujotzek</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Fuchs</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Qu</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Benz</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Klostermann</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Antes</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Georges</surname>
</string-name>, <source>mAbs</source>
<year>2015</year>, <volume>7</volume>, <fpage>838</fpage>&#x02013;<lpage>852</lpage>.<pub-id pub-id-type="pmid">26176812</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="anie201702403-cit-0018">
<string-name>
<given-names>J.</given-names>
<surname>Zhu</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Zhu</surname>
</string-name>, <string-name>
<given-names>D. W.</given-names>
<surname>Bougie</surname>
</string-name>, <string-name>
<given-names>R. H.</given-names>
<surname>Aster</surname>
</string-name>, <string-name>
<given-names>T. A.</given-names>
<surname>Springer</surname>
</string-name>, <source>Blood</source>
<year>2015</year>, <volume>126</volume>, <fpage>2138</fpage>&#x02013;<lpage>2145</lpage>.<pub-id pub-id-type="pmid">26282540</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="anie201702403-cit-0019">
<string-name>
<given-names>D. G.</given-names>
<surname>Johns</surname>
</string-name>, <string-name>
<given-names>T. L.</given-names>
<surname>Loo</surname>
</string-name>, <source>J. Pharm. Sci.</source>
<year>1967</year>, <volume>56</volume>, <fpage>356</fpage>&#x02013;<lpage>359</lpage>.</mixed-citation></ref><ref id="anie201702403-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="anie201702403-cit-0020">
<string-name>
<given-names>R. C.</given-names>
<surname>Donehower</surname>
</string-name>, <string-name>
<given-names>K. R.</given-names>
<surname>Hande</surname>
</string-name>, <string-name>
<given-names>J. C.</given-names>
<surname>Drake</surname>
</string-name>, <string-name>
<given-names>B. A.</given-names>
<surname>Chabner</surname>
</string-name>, <source>Clin. Pharmacol. Ther.</source>
<year>1979</year>, <volume>26</volume>, <fpage>63</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">445963</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="anie201702403-cit-0021">
<string-name>
<given-names>T. J.</given-names>
<surname>Haley</surname>
</string-name>, <source>Drug Metab. Rev.</source>
<year>1983</year>, <volume>14</volume>, <fpage>295</fpage>&#x02013;<lpage>335</lpage>.<pub-id pub-id-type="pmid">6341027</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="anie201702403-cit-0022">
<string-name>
<given-names>J.</given-names>
<surname>Heaton</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Rahmioglu</surname>
</string-name>, <string-name>
<given-names>K. R.</given-names>
<surname>Ahmadi</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Legido-Quigley</surname>
</string-name>, <string-name>
<given-names>N. W.</given-names>
<surname>Smith</surname>
</string-name>, <source>J. Pharm. Biomed. Anal.</source>
<year>2011</year>, <volume>55</volume>, <fpage>494</fpage>&#x02013;<lpage>499</lpage>.<pub-id pub-id-type="pmid">21377309</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="anie201702403-cit-0023">
<string-name>
<given-names>K.</given-names>
<surname>Pardee</surname>
</string-name>, <string-name>
<given-names>A. A.</given-names>
<surname>Green</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Ferrante</surname>
</string-name>, <string-name>
<given-names>D. E.</given-names>
<surname>Cameron</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>DaleyKeyser</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Yin</surname>
</string-name>, <string-name>
<given-names>J. J.</given-names>
<surname>Collins</surname>
</string-name>, <source>Cell</source>
<year>2014</year>, <volume>159</volume>, <fpage>940</fpage>&#x02013;<lpage>954</lpage>.<pub-id pub-id-type="pmid">25417167</pub-id></mixed-citation></ref><ref id="anie201702403-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="anie201702403-cit-0024">
<string-name>
<given-names>Z.</given-names>
<surname>Mao</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Mu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>Y. F.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Chi</surname>
</string-name>, <string-name>
<given-names>C. C.</given-names>
<surname>Lo</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Lien</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Xu</surname>
</string-name>, <source>Angew. Chem. Int. Ed.</source>
<year>2015</year>, <volume>54</volume>, <fpage>6270</fpage>&#x02013;<lpage>6273</lpage>;</mixed-citation><mixed-citation publication-type="journal" id="anie201702403-cit-0025">
<source>Angew. Chem.</source>
<year>2015</year>, <volume>127</volume>, <fpage>6368</fpage>&#x02013;<lpage>6371</lpage>.</mixed-citation></ref><ref id="anie201702403-bib-0025"><label>25</label><mixed-citation publication-type="book" id="anie201702403-cit-0026">
<string-name>
<given-names>D.</given-names>
<surname>Malacara</surname>
</string-name>, <source>Color Vision and Colorimetry: Theory and Applications</source>
<publisher-name>, 2nd ed.</publisher-name>, <publisher-loc>SPIE, Bellingham, WA</publisher-loc>, <year>2011</year>.</mixed-citation></ref><ref id="anie201702403-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="anie201702403-cit-0027">
<string-name>
<given-names>M.</given-names>
<surname>Colin</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Moritz</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Schneider</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Capeau</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Coutelle</surname>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Brahimi-Horn</surname>
</string-name>, <source>Gene Ther.</source>
<year>2000</year>, <volume>7</volume>, <fpage>1333</fpage>&#x02013;<lpage>1336</lpage>.<pub-id pub-id-type="pmid">10918505</pub-id></mixed-citation></ref></ref-list></back></article>